ArticleOral and maxillofacial surgery2026
The impact of patient age on the oncological prognosis of oral squamous cell carcinoma.
Article in Oral and maxillofacial surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEpidemiological data show that while age-standardized mortality rates of oral squamous cell carcinoma (OSCC) have slightly declined, the absolute number of deaths continues to rise, with a concerning increase among younger patients and persistently high mortality in the elderly. The aim of this study was to assess the influence of age on oncological prognosis and to classify it within a multivariable model alongside established histopathological risk factors.
methodsIn this retrospective single-center study, patients surgically treated for OSCC between 2012 and 2023 were included according to predefined eligibility criteria and stratified into three age groups (< 50, 50–69, ≥ 70 years). Primary endpoints were overall survival (OS) and disease-free survival (DFS). Prognostic factors were further evaluated with multivariable Cox regression models and competing-risk analyses, with age assessed both as a categorical and continuous variable using restricted cubic splines.
resultsIn 525 included patients (mean age 63.5 years), age distribution was multimodal with three peaks in concordance with the predefined groups. Local recurrence, distant metastasis, and secondary cervical lymph node metastasis (CLNM) were weakly correlated overall, with a stronger association between CLNM and distant metastasis in younger patients. Age significantly predicted overall survival (HR per 10 years: 1.56, 95% CI: 1.29–1.90), but showed no independent association with disease-free survival.
conclusionsAge presented with a multimodal distribution with distinct clinical patterns across the subgroups and was independently associated with worse OS. Nevertheless, no association was observed for DFS, suggesting that age-related differences in mortality may be influenced by non-oncologic factors. While correlations between recurrence events were generally weak, younger patients displayed a stronger link between regional and distant metastasis, emphasizing the importance of age-related follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.